Mabxience Allies With Zentiva For European Bevacizumab Launch
Avastin Rival Alymsys Launched Shortly After Partner Stada Introduced Oyavas
Mabxience and Zentiva have partnered to launch the Alymsys bevacizumab biosimilar rival to Avastin that recently received a pan-European marketing authorization.
You may also be interested in...
The FDA’s acceptance of Amneal’s filing for bevacizumab brings the company a step closer to its goal of launching a US biosimilar every year to 2023.
Viatris and Biocon Biologics are now in a position to enter the European market for biosimilar bevacizumab, after the European Commission formally approved the pair’s Abevmy rival to Avastin.
Several biosimilars to Roche’s Avastin are now available in Europe following market formation in June last year, adding to Roche’s woes for its legacy oncology drugs, including MabThera/Rituxan and Herceptin.